Literature DB >> 34714158

Immediate Lymphatic Reconstruction to Prevent Breast Cancer-Related Lymphedema: A Systematic Review.

Julia A Cook1, Mithun Sinha1,2, Mary Lester1, Carla S Fisher3, Chandan K Sen1,2, Aladdin H Hassanein1,2.   

Abstract

Significance: Lymphedema is chronic limb swelling from lymphatic dysfunction. The condition affects up to 250 million people worldwide. In breast cancer patients, lymphedema occurs in 30% who undergo axillary lymph node dissection (ALND). Recent Advances: Immediate lymphatic reconstruction (ILR), also termed Lymphatic Microsurgical Preventing Healing Approach (LyMPHA), is a method to decrease the risk of lymphedema by performing prophylactic lymphovenous anastomoses at the time of ALND. The objective of this study is to assess the risk reduction of ILR in preventing lymphedema. Critical Issues: Lymphedema has significant effects on the quality of life and morbidity of patients. Several techniques have been described to manage lymphedema after development, but prophylactic treatment of lymphedema with ILR may decrease risk of development to 6.6%. Future Directions: Long-term studies that demonstrate efficacy of ILR may allow for prophylactic management of lymphedema in the patient undergoing lymph node dissection.

Entities:  

Keywords:  LyMPHA; lymphatic reconstruction; lymphedema microsurgical prevention healing approach; lymphovenous anastomosis

Mesh:

Year:  2022        PMID: 34714158     DOI: 10.1089/wound.2021.0056

Source DB:  PubMed          Journal:  Adv Wound Care (New Rochelle)        ISSN: 2162-1918            Impact factor:   4.730


  2 in total

1.  Distally Prophylactic Lymphaticovenular Anastomoses after Axillary or Inguinal Complete Lymph Node Dissection Followed by Radiotherapy: A Case Series.

Authors:  Diletta Maria Pierazzi; Sergio Arleo; Gianpaolo Faini
Journal:  Medicina (Kaunas)       Date:  2022-01-29       Impact factor: 2.430

2.  Visual analysis of global research output of lymphedema based on bibliometrics.

Authors:  Yun-Dong Zhang; Xue Zhang; Xin-Yu Wang; Dong-Mei Han; Jian-Shi Du
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.